CUX1 (cut-like homeobox 1) is a transcription factor, which is localized to human chromosome 7q22.1. It is also known as CCAAT-displacement protein (CDP) or Cut-like1 (CUTL1). This protein has two isoforms, a full length called p200 CUX1 and a cathepsin L processed form called p110 CUX1. These differ in their DNA-binding capacities, and transcriptional properties.
Synonyms: Anti-CASP; Anti-CDP; Anti-CDP/Cut; Anti-CDP/Cux; Anti-CDP1; Anti-CUT; Anti-CUTL1; Anti-CUX; Anti-Clox; Anti-Cux/CDP; Anti-GOLIM6; Anti-cut-like homeobox 1
Storage: -20C
Application: All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry. The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.
Biochem Physiol Actions: CUX1 (cut-like homeobox 1) mediates tumor cell survival by suppressing apoptosis in pancreatic cancer. The cux genes are involved in dendrite branching, spine development, and synapse formation. This protein can control transcription in a long-range manner, and can control multiple in a certain loci. This gene is involved in tumorigenesis, and its expression in breast cancer is generally linked to less differentiated state and poor overall patient survival. In human insulinomas, it promotes pro-angiogenic invasive and malignant phenotype.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC